

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



友芝友生物製藥

## **WUHAN YZY BIOPHARMA CO., LTD.**

### **武漢友芝友生物製藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2496)**

## **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON THURSDAY, JUNE 27, 2024**

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) is pleased to announce the poll results of the annual general meeting (the “**AGM**”) held on Thursday, June 27, 2024.

For details of the resolutions considered at the AGM, the shareholders of the Company (the “**Shareholders**”) may refer to the notice of the AGM and the Company’s circular both dated May 29, 2024 (the “**Circular**”). Unless otherwise defined, capitalized terms in this announcement shall have the same meanings as those defined in the Circular.

### **CONVENING AND ATTENDANCE OF THE AGM**

The AGM was held as an on-site meeting at Conference Room 210, 2nd Floor, Building C2-1, No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Wuhan, Hubei Province, PRC on Thursday, June 27, 2024.

The AGM was convened by the Board and hosted by Dr. Zhou Pengfei, the chairman of the Board. All the Directors attended the AGM, either in person or online.

The convention of the AGM was in compliance with the requirements of the applicable PRC laws and regulations, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company (the “**Articles of Association**”). All the proposed resolutions as set out in the notice of the AGM were tabled before the AGM for Shareholders’ consideration and approval, and were put to vote by way of poll.

To the best knowledge of the Board, having made reasonable inquiries (i) there was no restriction on any Shareholder casting votes on any proposed resolution at the AGM; (ii) no Shareholder has a material interest in the matter considered at the AGM and was required to abstain from voting at the AGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favour of the resolution proposed at the AGM as set out in Rule 13.40 of the Listing Rules; and (iv) no party has stated any intention in the Circular to vote against or abstain from voting on any resolution proposed at the AGM.

## POLL RESULTS OF THE AGM

As at the date of the AGM, the total number of issued Shares and Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM was 193,849,200, including 82,380,386 Unlisted Shares and 111,468,814 H Shares. The number of Shareholders and authorized proxies attended the AGM was three. Shareholders and authorized proxies holding an aggregate of 173,382,817 Shares attended the AGM, representing approximately 89.44% of the total number of Shares with voting rights.

At the AGM, the following resolutions were considered and passed by registered poll and the poll results are set out as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the Annual Report for 2023.	173,382,817 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the report of the Board of Directors for 2023 of the Company.	173,382,816 (100.00%)	0 (0.00%)	1 (0.00%)
3.	To consider and approve the report of the Supervisory Committee for 2023 of the Company.	173,382,817 (100.00%)	0 (0.00%)	0 (0.00%)
4.	To consider and approve the report of the financial report for 2023 of the Company.	173,382,817 (100.00%)	0 (0.00%)	0 (0.00%)
5.	To consider and approve the report of the profit distribution plan for 2023 of the Company.	173,382,817 (100.00%)	0 (0.00%)	0 (0.00%)
6.	To consider and approve the proposed reappointment of the auditor for 2024.	173,382,817 (100.00%)	0 (0.00%)	0 (0.00%)
Special Resolutions		Number of Votes (%)		
		For	Against	Abstain
7.	To consider and approve the proposed grant of Issuance Mandate.	163,362,369 (94.22%)	1,620,448 (0.93%)	8,400,000 (4.84%)
8.	To consider and approve the proposed adoption of the 2024 H Share Option Plan.	163,362,369 (94.22%)	10,020,448 (5.78%)	0 (0.00%)
9.	Conditional upon the above special resolution No. 8 being duly passed, to consider and approve the Plan Mandate Limit.	163,362,369 (94.22%)	10,020,448 (5.78%)	0 (0.00%)
10.	Conditional upon the above special resolutions No. 8 and No. 9 being duly passed, to consider and approve the Service Provider Sublimit.	163,362,369 (94.22%)	10,020,448 (5.78%)	0 (0.00%)
11.	To consider and approve the proposed amendments to the Articles of Association.	171,762,369 (99.07%)	1,620,448 (0.93%)	0 (0.00%)

As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 6, such resolutions were duly passed as ordinary resolutions. As more than two-thirds of the votes were cast in favour of each of the resolutions numbered 7 to 11, such resolutions were duly passed as special resolutions.

## **SCRUTINEERS**

The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, two Shareholders' representatives, two supervisors of the Company and a lawyer from Beijing Dentons Law Offices, LLP (WUHAN), the PRC legal adviser of the Company, served as the scrutineers of the AGM for scrutinizing and counting votes.

By order of the Board  
**Wuhan YZY Biopharma Co., Ltd.**  
**Dr. Zhou Pengfei**  
*Chairman of the Board, Executive  
Director and Chief Executive Officer*

Wuhan, PRC, June 27, 2024

*As at the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director, Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive Directors, and Dr. Cheng Bin, Dr. Dai Weiguo, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.*